Havisure— India’s first home-developed vaccine for Hepatitis A has made it appearance. Indian Immunologicals Ltd (IIL), which is owned by the National Dairy Development Board (NDDB), has made the vaccine. The aim is to put up a significant step forward in India’s fight against Hepatitis A. It is a viral infection primarily spread through the fecal-oral route, meaning that it is transmitted through the ingestion of contaminated food or water.
The novel vaccine was introduced with a launch in Hyderabad. Chief guests were Shri Nagaraj Karpan, MLA and Shri Ajay Mishra, IAS-Chairman Indian Redcross Society, Telangana.
Researchers and scientists of IIL worked towards achieving this milestone. This vaccine is poised to play a crucial role in preventing the disease dedicated to play a crucial role in preventing the disease. The vaccine is effective in preventing the disease and is recommended for children in the routine immunization. It is a two-dose vaccine wherein the first dose is administered at above 12 months of age and the second dose is given at least after 6 months of the first dose. The vaccine is also recommended for individuals who are at risk of exposure or travel to the regions with high hepatitis A prevalence. In addition to this people with occupational risk of infection and suffering from chronic liver diseases also need Hepatitis A vaccination.
Speaking on the occasion, Dr. K Anand Kumar, Managing Director, Indian Immunologicals Ltd said: “The launch of Havisure is a testament to our commitment to advancing healthcare solutions for the nation. Currently, Hepatitis A vaccines are imported into our country and as a true meaning of Atma Nirbhar Bharat, IIL has tirelessly put in efforts and developed India’s 1st vaccine for Hepatitis A. The vaccine has undergone extensive clinical trials in 8 centers and has proven to be safe and efficacious. With Havisure, we aim to contribute significantly to the prevention of this infectious disease. IIL launching three vaccines in a single year is itself a big achievement and the credit goes to my team.”
Discussing on manufacturing capabilities of IIL, Dr. Priyabrata Pattnaik, Dy. Managing Director-IIL said, “The company has considerably invested in state-of-the-art manufacturing facilities to scale up production and meet the growing demand for Hepatitis A vaccine. As part of the launch, IIL will be collaborating with healthcare professionals, corporate hospitals, and government agencies to promote awareness about Hepatitis A and the importance of both paediatric, adolescent & adult vaccination.”
Follow us
